Literature DB >> 30978430

Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.

Mona A Elhosary1, Mohammed Bahey-El-Din2, Amany AbdelBary3, Nadia El Guink1, Hamida M Aboushleib1.   

Abstract

Pseudomonas aeruginosa is a notorious pathogen with increasing multi-drug resistance. This situation makes it urgent to develop a prophylactic vaccine against this pathogen. Different virulence factors play a crucial role in P. aeruginosa infection. This study focused on evaluation of the iron acquisition protein HitA as a potential vaccine candidate against P. aeruginosa in a murine infection model. The recombinant ferric iron-binding periplasmic protein HitA was overexpressed in Escherichia coli and was purified using metal affinity chromatography. The purified antigen was administered to mice in combination with Bacillus Calmette-Guérin (BCG) as an adjuvant using different vaccination regimens. Serum samples were tested for IgG1, IgG2a and total IgG antibody responses which were extremely significant. Following challenge of mice with P. aeruginosa, there was a significant reduction in bacterial load in lungs of immunized mice compared to negative control mice. Opsonophagocytic assay supported the previous results. In addition, histopathological examination of livers of challenged mice showed a significant improvement difference between immunized mice and negative control mice in various histopathological parameters. Up to our knowledge, this is the first report that investigates HitA as a potential vaccine antigen. Overall, the results of this study demonstrate the protective effect of HitA recombinant protein and highlight its importance as a promising vaccine candidate against P. aeruginosa infection.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BCG; HitA; Iron acquisition; Iron-binding protein; Pseudomonas aeruginosa; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 30978430     DOI: 10.1016/j.micpath.2019.04.014

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

Review 1.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

Review 2.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

3.  Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Ziqiang Guan; Wei Sun
Journal:  mSphere       Date:  2021-10-06       Impact factor: 5.029

4.  Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections.

Authors:  Robert J Hart; Lisa A Morici
Journal:  Front Microbiol       Date:  2022-03-28       Impact factor: 5.640

5.  Functional Annotation of Hypothetical Proteins From the Enterobacter cloacae B13 Strain and Its Association With Pathogenicity.

Authors:  Supantha Dey; Sazzad Shahrear; Maliha Afroj Zinnia; Ahnaf Tajwar; Abul Bashar Mir Md Khademul Islam
Journal:  Bioinform Biol Insights       Date:  2022-08-06

6.  Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats.

Authors:  Salah A Sheweita; Amro A Amara; Heba Gamal; Amany A Ghazy; Ahmed Hussein; Mohammed Bahey-El-Din
Journal:  Vaccines (Basel)       Date:  2022-06-07

7.  Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection.

Authors:  Peng Li; Xiuran Wang; Xiangwan Sun; Jesse Cimino; Ziqiang Guan; Wei Sun
Journal:  Infect Immun       Date:  2021-07-26       Impact factor: 3.609

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.